Mitochondrial Delivery of an Anticancer Drug Via Systemic Administration Using a Mitochondrial Delivery System That Inhibits the Growth of Drug-Resistant Cancer Engrafted on Mice

Validation of the Mitochondrial Delivery of Vitamin B1 to Enhance ATP Production Using SH-SY5Y Cells, a Model Neuroblast

“…We previously developed a MITO-Porter 3-8 a liposomal DDS for delivering cargoes to mitochondria, and reported that such a MITO-Porter system successfully delivered various cargoes including lowmolecular-weight compounds (e.g., anti-cancer drugs, 9 a porphyrintype chemical, 10 coenzyme Q 10 11 ) and macromolecules such as nucleic acids [12][13][14][15] to mitochondria via mitochondrial membrane fusion. We assumed that the MITO-Porter system could accelerate the cellular uptake of vitamin B 1 and would eventually reach the mitochondria.…”

Mitochondria targeting drugs for neurodegenerative diseases—Design, mechanism and application

“…To achieve mitochondria targeting, many strategies have been proposed and verified to be feasible ( Fig. 1 and Table 1 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ).

Figure 1 The structures of small molecules and peptides with mitochondria targeting ability.

…”

Evolution of drug delivery system from viewpoint of controlled intracellular trafficking and selective tissue targeting toward future nanomedicine

“…Research directed toward the development of nanomedicines based on MITO-Porter technology includes fields such as mitochondrial gene therapy [ [77] , [78] , [79] ], cancer therapy [ [80] , [81] , [82] , [83] , [84] ], ischemic diseases therapy [ 85 , 86 ] and cell therapy [ 87 ]. Our research outcomes regarding validating a mitochondrial gene therapeutic strategy are summarized in the following section, with a particular focus on mitochondrial RNA therapy.…”